Results 21 to 30 of about 5,643 (237)
An E2 ubiquitin-conjugating enzyme links diubiquitinated H2B to H3K27M oncohistone function [PDF]
Proceedings of the National Academy of SciencesThe H3K27M oncogenic histone (oncohistone) mutation drives ~80% of incurable childhood brain tumors known as diffuse midline gliomas (DMGs). The major molecular feature of H3K27M mutant DMGs is a global loss of H3K27 trimethylation (H3K27me3), a ...
Jiao, Alan L +4 more
core +5 more sources
The H3K36me2 writer-reader dependency in H3K27M-DIPG [PDF]
Science Advances, 2021 The H3K36me2 histone modification pathway is an acquired dependency in H3K27M mutant diffuse intrinsic pontine glioma (DIPG).
Jia-Ray Yu +9 more
openaire +4 more sources
Does H3K27M Mutation Impact Survival Outcome of High-Grade Spinal Cord Astrocytoma? [PDF]
Neurospine, 2023 Objective To evaluate the impact of H3K27M mutation in the prognosis of histological high-grade intramedullary astrocytoma. Methods A total of 78 patients who were diagnosed with high-grade spinal cord astrocytoma were included.
Fan Zhang +10 more
doaj +1 more source
Liquid biopsy in H3K27M diffuse midline glioma
Neuro-Oncology, 2023 Abstract Diffuse midline glioma (DMG) with H3K27M mutation is an aggressive and difficult to treat pediatric brain tumor. Recurrent gain of function mutations in H3.3 (H3.3A) and H3.1 (H3C2) at the 27th lysine to methionine (H3K27M) are seen in over 2/3 of DMGs, and are associated with a worse prognosis. Due to the anatomical location of
Jina Patel +9 more
openaire +3 more sources
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma [PDF]
Current Oncology Reports, 2020 H3K27M is a frequent histone mutation within diffuse midline gliomas and is associated with a dismal prognosis, so much so that the 2016 CNS WHO classification system created a specific category of "Diffuse Midline Glioma, H3K27M-mutant". Here we outline the latest pre-clinical data and ongoing current clinical trials that target H3K27M, as well as ...
Kyle, Wierzbicki +12 more
openaire +2 more sources
GENE-45. DISSECTING THE DRIVERS OF ADULT H3K27M-GLIOMAS AT THE SINGLE-CELL LEVEL [PDF]
Science, 2019 Cancer Genomics Diffuse midline gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-glioma) are an aggressive type of childhood cancer with few options for treatment. Filbin et al. used a single-cell sequencing approach to study the oncogenic programs, genetics, and cellular hierarchies of H3K27M-glioma.
Ilon Liu +8 more
openalex +2 more sources
Neurological Research and Practice, 2023 Introduction Diffuse midline gliomas (DMG) are universally lethal central nervous system tumors that carry almost unanimously the clonal driver mutation histone-3 K27M (H3K27M).
Niklas Grassl +24 more
doaj +1 more source
H3K27M mutant glioma: Disease definition and biological underpinnings
Neuro-Oncology, 2023 Abstract High-grade glioma (HGG) is the most common cause of cancer death in children and the most common primary central nervous system tumor in adults. While pediatric HGG was once thought to be biologically similar to the adult form of disease, research has shown these malignancies to be significantly molecularly distinct ...
Saratsis, Amanda M +3 more
openaire +3 more sources
Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker
Indian Journal of Pathology and Microbiology, 2021 Diffuse Midline Glioma-H3K27M mutant is a specific entity added to the 2016 updated WHO classification of CNS tumours that represents the majority of diffuse intrinsic pontine gliomas, although identical tumours are also found elsewhere in the midline ...
Prachi Agarwal, Hema Malini Aiyer
doaj +1 more source
Neoplasia: An International Journal for Oncology Research, 2023 Therapeutic resistance remains a major obstacle to preventing progression of H3K27M-altered Diffuse Midline Glioma (DMG). Resistance is driven in part by ALDH-positive cancer stem cells (CSC), with high ALDH1A3 expression observed in H3K27M-mutant DMG ...
Monika Sharma +13 more
doaj +1 more source